PEA (palmitoylethanolamide)
Sleep & Recovery · Endogenous fatty acid amide
Tier B+
Bottom line
Read Off Label grades PEA (palmitoylethanolamide) as B+ (7.1/10) based on moderate evidence, med benefit magnitude, and a low-risk safety profile.
Italian research tradition.
Studied, labeled, or reported-use context: 300-1200 mg/day PO; ultramicronized formulations produce higher measured bioavailability — Rx (Italy/Spain as Normast/Pelvilen); OTC supplement elsewhere; not individualized guidance.
What the evidence says
Italian research tradition. Ultramicronized (um-PEA) form has better absorption than standard. Gabapentinoid-sparing in some chronic pain regimens. Synergistic with luteolin in some formulations.
Mechanism
Endocannabinoid-like fatty acid amide; PPAR-α agonist; 'entourage' amplification of endogenous anandamide; anti-inflammatory and analgesic via mast cell modulation
Studied, labeled, or reported dose & route
300-1200 mg/day PO; ultramicronized formulations produce higher measured bioavailability
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about PEA (palmitoylethanolamide)'s effects?
- Read Off Label rates the evidence for PEA (palmitoylethanolamide) as Moderate and the benefit magnitude as med, producing an overall grade of B+ (7.1/10). Italian research tradition.
- What safety findings are reported for PEA (palmitoylethanolamide)?
- PEA (palmitoylethanolamide) has a low risk profile in the database. Low (very well-tolerated; rare GI) Legal status: Rx (Italy/Spain as Normast/Pelvilen); OTC supplement elsewhere.
- What doses or routes are reported for PEA (palmitoylethanolamide)?
- 300-1200 mg/day PO; ultramicronized formulations produce higher measured bioavailability This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does PEA (palmitoylethanolamide) work?
- Endocannabinoid-like fatty acid amide; PPAR-α agonist; 'entourage' amplification of endogenous anandamide; anti-inflammatory and analgesic via mast cell modulation
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.